(TXMD) TherapeuticsMD, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TXMD) TherapeuticsMD, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This TherapeuticsMD, Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing strategy, distribution channels, and promotional tactics to show how it competes in women’s health. The page includes a real preview/sample of the analysis so you can evaluate style and depth before buying—purchase the full version to receive the complete, ready-to-use report.
Product
IMVEXXY
IMVEXXY is TherapeuticsMD, Inc.'s prescription vaginal estradiol softgel insert for moderate to severe dyspareunia linked to menopause, with 4 mcg and 10 mcg strengths. It is a core women's health brand in TherapeuticsMD’s portfolio and is aimed at relieving menopausal vaginal symptoms. In the 4P mix, the product stands out as a low-dose, local estrogen therapy with a defined Rx-only use case.
BIJUVA
BIJUVA pairs 17β-estradiol and progesterone in one oral capsule, positioning TherapeuticsMD, Inc. in bio-identical hormone replacement therapy for moderate to severe vasomotor symptoms. In the REPLENISH trial, 1,835 postmenopausal women were studied, and the product was approved by the U.S. FDA in 2018. That clinical base supports its Product strategy as a prescription HRT option with strong brand differentiation.
ANNOVERA
ANNOVERA is a one-year, reusable vaginal ring contraceptive that gives TherapeuticsMD a non-pill, non-daily option in reproductive health. In pivotal studies, its Pearl Index was 2.98 pregnancies per 100 woman-years, supporting its role as a long-acting birth control choice. It broadens the Company’s women’s health portfolio with a format designed for 13 cycles of use.
Prescription prenatal vitamins
TherapeuticsMD's prescription prenatal vitamins, including vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1, extend the Product mix into maternal nutrition, not just therapeutics. The line fits a niche with recurring demand from pregnant patients and prescribers who want branded and generic options.
- Branded plus generic prenatal Rx
- Four named labels
- Maternal nutrition expansion
This product set supports cross-selling in OB/GYN channels and helps the Company diversify beyond hormone-based drugs.
Pipeline candidates TX-005HR to TX-009HR
TherapeuticsMD, Inc. lists TX-005HR to TX-009HR as preclinical hormone-related candidates, spanning cream, patch, and oral formats. The set shows a clear women’s health focus, but these assets are still early-stage and not yet revenue drivers.
For the 4P view, the product strategy is pipeline breadth: multiple delivery forms can support future positioning by patient preference and compliance. One key fact: preclinical assets carry high development risk, so value depends on proof of safety and efficacy, not current sales.
- Five candidates: TX-005HR to TX-009HR
- Formats: cream, patch, oral
- Status: preclinical
- Focus: women’s health
TherapeuticsMD’s Women’s Health Portfolio Spans Multiple High-Need Markets
TherapeuticsMD, Inc.’s Product mix is built on four marketed women’s health brands: IMVEXXY, BIJUVA, ANNOVERA, and prenatal Rx lines. The set spans menopause, contraception, and maternal nutrition, so the Company uses one OB/GYN channel across multiple needs. Early-stage TX-005HR to TX-009HR add pipeline depth, but they are still preclinical.
| Product | Status | Use |
|---|---|---|
| IMVEXXY | Marketed | Vaginal estradiol |
| ANNOVERA | Marketed | 1-year contraception |
What is included in the product
Detailed Word Document
Provides a concise, company-specific 4P’s analysis of TherapeuticsMD, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses TherapeuticsMD’s 4Ps into a quick, clear snapshot that eases strategic review and decision-making.
Reference Sources
Provides a concise, traceable list of primary sources (industry reports, FDA filings, financials) to validate TherapeuticsMD market, pricing, and competitive assumptions.
Place
Boca Raton, Florida headquarters
TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida, where it was founded in 2008. The Boca Raton base anchors its U.S. corporate, commercial, and development functions, keeping leadership, planning, and execution close together. As of 2026, this Florida hub remains the company’s main operating center for its commercial and pipeline work.
Wholesale pharmacy distributors
TherapeuticsMD, Inc. uses wholesale pharmacy distributors to reach pharmacies fast and at scale. In the U.S., wholesalers handle about 90% of prescription drug distribution, so this channel is the standard route for inventory flow and broad patient access. For prescription products, that reach matters more than direct sales because it supports consistent stock at the point of care.
Retail pharmacy distributors
TherapeuticsMD uses retail pharmacy distributors to place women’s health products where prescriptions are filled, so access is close to the patient. In the U.S., about 90% of prescriptions are dispensed through retail pharmacies, making this channel central to therapy start and refill rates. That reach helps support steady use of ongoing treatments.
Prescription drug channels
IMVEXXY, BIJUVA, and ANNOVERA are prescription-only products, so access depends on a healthcare provider’s order and pharmacy dispensing. TherapeuticsMD’s place strategy is built around OB-GYN, primary care, and specialty pharmacy channels, which fits a Rx market where distribution runs through medical and pharmacy infrastructure. This channel setup supports targeted access, but each fill still depends on payer coverage and prior authorization.
- Provider prescribing drives access
- Pharmacies complete dispensing
- Specialty and payer checks matter
Prenatal vitamin distribution
Prenatal vitamin distribution sits beside TherapeuticsMD, Inc.'s prescription portfolio, so branded and generic products can move through the same pharmacy channels. That widens reach beyond core therapeutics and gives the Company a broader retail footprint without building a separate sales route.
- Shared pharmacy networks
- Broader market reach
- Lower channel complexity
TherapeuticsMD’s U.S. Pharmacy Strategy Keeps Products Close to the Point of Fill
TherapeuticsMD’s Place strategy is U.S.-centric: prescription products move from OB-GYN, primary care, and specialty channels into retail and wholesale pharmacies, where about 90% of prescriptions are dispensed. That keeps IMVEXXY, BIJUVA, and ANNOVERA close to the point of fill, but each dispense still depends on payer approval and prior authorization. Its Boca Raton, Florida base supports centralized commercial control.
| Place element | Latest data point | Why it matters |
|---|---|---|
| U.S. pharmacy channel | ~90% of prescriptions dispensed retail | Supports broad patient access |
| Wholesale distribution | ~90% of drug distribution | Moves inventory at scale |
What You See Is What You Get
TherapeuticsMD, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises.
This is the same ready-made Marketing Mix document you'll download immediately after checkout, covering TherapeuticsMD, Inc.'s Product, Price, Place, and Promotion in a concise, actionable format.
Promotion
Women’s health positioning
TherapeuticsMD’s promotion is tightly centered on women’s health, with core products aimed at menopause, dyspareunia, contraception, and prenatal nutrition. That 4-area focus gives the brand a clear medical identity and helps it speak to one patient base with specific needs. In 2025, this niche positioning still matters because it keeps the message focused, clinical, and easy for prescribers to place.
Brand-led portfolio names
TherapeuticsMD uses three clear brand names—IMVEXXY, BIJUVA, and ANNOVERA—to make each prescription therapy easier to spot in a crowded market. Brand-led naming supports recall with prescribers and patients, and it helps separate products by use case: vaginal estrogen, oral hormone therapy, and contraception. That cleaner brand map can sharpen promotion and reduce mix-ups.
Physician prescribing pathway
TherapeuticsMD’s promotion leans on physician prescribing, because Rx drugs are bought through healthcare professionals, not end users. For products like IMVEXXY, BIJUVA, and ANNOVERA, the message must stress FDA-approved indications, safety, and patient fit; that makes clinician education the core lever, especially in a market where one prescriber can drive 100% of dispensing.
Disease-state messaging
TherapeuticsMD, Inc. uses disease-state messaging to tie each brand to a clear need: vasomotor symptoms and dyspareunia for BIJUVA and IMVEXXY, plus contraception for ANNOVERA. That matters because the company serves three defined use cases, not a broad wellness story, which makes outreach sharper for clinicians and easier for patients to understand. In the U.S., about 6,000 women reach menopause each day, so condition-based framing stays highly relevant.
- 3 products, 3 defined needs
- 2 menopause symptoms
- 1 contraception option
Prenatal nutrition branding
TherapeuticsMD, Inc. uses vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 to add four consumer-facing brands to its prenatal nutrition mix. That matters because prenatal vitamins sit in a large, repeat-purchase category, so stronger brand recall can support trial and refill. It also gives TherapeuticsMD, Inc. reach beyond hormone therapies and into everyday women’s health.
- 4 prenatal brand assets
- Boosts category recognition
- Expands beyond hormone therapies
TherapeuticsMD Keeps Women’s Health Focus Tight and Clinical
TherapeuticsMD, Inc. promotion stays narrow and prescriber-led: 3 Rx brands—IMVEXXY, BIJUVA, and ANNOVERA—map to 3 clear uses. It also adds 4 prenatal names—vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1—to widen reach. In 2025, that focused women’s-health mix keeps messaging clinical and easy to place.
| Metric | Data |
|---|---|
| Rx brands | 3 |
| Prenatal names | 4 |
| Core focus | Women’s health |
Price
Prescription-based pricing
TherapeuticsMD sells prescription medicines and prescription vitamins, so its price is set mainly through pharmacy and payer channels, not direct retail. The final patient cost depends on the dispensing pharmacy, insurance coverage, formulary status, and any rebates or copay support. In this model, the list price matters less than net realized price after payer discounts and patient benefit design.
Insurance and reimbursement
Insurance coverage is a key gatekeeper for TherapeuticsMD, Inc. branded women’s health drugs, because prior auth and formulary tiering can decide access. Reimbursement also drives out-of-pocket cost; branded drug copays can run from about $25 to $100+ per fill, while self-pay can be much higher. For chronic therapies, that gap can decide persistence and refill rates.
Branded and generic vitamin tiers
TherapeuticsMD, Inc. sells branded and generic prenatal vitamins, so it can price one category at two tiers. That helps cover premium and value buyers and gives prescribers more choice when cost matters. In 2025, this kind of mixed pricing stayed important as patients kept looking for lower out-of-pocket options while keeping access to the same core prenatal use.
Specialty women’s health value
BIJUVA, IMVEXXY, and ANNOVERA are prescription-only women’s health products with narrow uses, so their value comes from clinical fit and payer access, not mass-market volume. ANNOVERA lasts up to 1 year per ring, while BIJUVA and IMVEXXY support hormone-therapy use, which helps justify premium drug pricing versus consumer goods.
- Prescription-only, specialist use
- Premium pricing supports value
- Access depends on coverage
No public shelf-price model
TherapeuticsMD does not use a shelf-price model. In pharmacy channels, the final transaction price is set by payer contracts, rebates, and dispensing fees, so end users usually do not see a clear list price. That makes pricing less visible than a retail brand and more tied to coverage terms.
- No public shelf tag
- Price shaped by payers
- Hidden net price at checkout
Payer Contracts, Not Shelf Price, Set TherapeuticsMD’s Real Revenue
TherapeuticsMD’s price is mostly payer-set, not shelf-set, so net realized price depends on rebates, formulary tier, and copays. ANNOVERA’s 1-year duration and BIJUVA/IMVEXXY’s specialist use support premium pricing, but coverage still drives what patients pay. In 2025, branded copays often ran $25-$100+ per fill.
| Price driver | Impact |
|---|---|
| Payer contracts | Sets net price |
| Copays | $25-$100+ per fill |
| ANNOVERA | 1-year use |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.